Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis
Open Access
- 27 February 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 145 (9) , 956-969
Abstract
Anti-CD19 chimeric antigen receptor (CAR)–engineered T and natural killer (NK) cell therapies have revolutionized the treatment of B-cell malignancies, but challenges including CD19 antigen loss greatly hinder their full therapeutic potential. Here, we revealed that cotreatment with anti-CD19 monoclonal antibody enhances antitumor activity of anti-CD19 CAR-T and -NK cells. Even though the treated antibody interferes with CD19 antigen binding of CAR, it significantly induces rapid detachment of anti-CD19 CAR effector cells from target cells, facilitating improved serial killing. This reduced interaction between CAR effector cells and target cells also leads to the alleviation of CAR-mediated trogocytosis. Interestingly, cotreatment with anti-CD19 antibody reveals time-dependent effects on the antitumor activity of anti-CD19 CAR-T cells, characterized by a reduction in early T cell activation followed by sustained high activity during prolonged exposure to target cells. This temporal modulation ultimately results in enhanced antitumor potency in vivo. These findings underscore the improved therapeutic efficacy achieved by combining anti-CD19 antibody with anti-CD19 CAR-T or -NK cells against B-cell malignancies.Keywords
This publication has 33 references indexed in Scilit:
- Accurate identification of cell doublet profiles: Comparison of light scattering with fluorescence measurement techniquesCytometry Part A, 2022
- Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomesMed, 2022
- Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansionLeukemia, 2022
- CAR T-cell therapy and critical careWiener klinische Wochenschrift, 2021
- Cross-reactivity of mouse IgG subclasses to human Fc gamma receptors: Antibody deglycosylation only eliminates IgG2b bindingMolecular Immunology, 2020
- CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?Pharmacological Research, 2018
- Engineering Natural Killer Cells for Cancer ImmunotherapyMolecular Therapy, 2017
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activityLeukemia, 2017
- The Principles of Engineering Immune Cells to Treat CancerCell, 2017
- Antibody therapy of cancerNature Reviews Cancer, 2012